Company intelligence / Profile preview

Lovaltech

Ownership: Private
Employees: ~19
Development stage: Other

Overview

Lovaltech has developed an innovative intranasal recombinant protein-based COVID‑19 vaccine candidate, LVT‑001. The first GMP clinical batch was released in March 2025. The company received regulatory approval to begin a Phase 1 trial (“MUCOBOOST”) in France by April/May 2025 with plans for a larger Phase 2 study in early 2026. The technology aims to induce both systemic and mucosal immunity, potentially blocking infection and transmission—including emerging variants—offering advantages over current mRNA vaccines. No published clinical results yet as trials are just commencing.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinVaccineProteinIntranasal delivery device
Industry: Biotech

Drug pipeline

2 assets

LVT-001

1 more asset in the full pipeline.

Request access →

Partnerships

Aptar PharmaGTP Bioways CDMOUniversity of Tours regional hospital centerInserm’s Emerging Infectious Diseases agency

Beyond the preview

Go deeper on Lovaltech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lovaltech.

Explore the full profile